C5a Protein (Native)

Complement Component C5a / C5a Protein

C5a Protein Product Information

• Synonym: CPAMD4 , FLJ17816 , FLJ17822 , MGC142298
• Protein Construction: A DNA sequence encoding the active form of human C5a ( Leu 679 - Arg 751 ) was expressed
• Source: Human
• Expression Host: E.coli

C5a Protein QC Testing

• Purity: > 94 % as determined by SDS-PAGE
• Bio-activity: Measured by its ability to induce N-acetyl-ß-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells.
  The ED₅₀ for this effect is typically 5-15 ng / ml
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Based on N-terminal sequencing analysis, the first 7 aa of C5a is: MLQKKIE
• Molecular Mass: The recombinant human C5a consists of 74 amino acids and has a predicted molecular mass of 8.3 kDa which is also estimated by SDS-PAGE
• Formulation: Lyophilized from sterile PBS, pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: C5a protein

C5a Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

C5a Protein Description

C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a exerts actions by binding to G-protein-coupled receptor (C5aR/CD88) on the plasma membrane of target cells. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis.

References

1. Gerard C. et al., 1994, Annu Rev Immunol. 12: 775-808.
2. Markus S. et al., 2003, J Immunol. 170: 6115-24.
3. Sumichika H. et al., 2002, J Biol Chem. 277: 49403-7.
4. Riedemann NC. et al., 2004, J Immunol. 173: 1355-9.
5. Hsu MH. et al., 1999, Blood. 10: 3241-9.
6. Monk PN. et al., 2007, British Journal of Pharmacology. 152: 429-48.